{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DMX"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DMX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DMX\",,,,,undefined,":{"symbol":"DMX","market":"US","secType":"STK","nameCN":"DoubleLine Multi-Sector Income ETF","latestPrice":49.58,"timestamp":1746820800000,"preClose":49.545,"halted":0,"volume":3977,"hourTrading":{"tag":"盘后","latestPrice":49.57,"preClose":49.58,"latestTime":"16:05 EDT","volume":2,"amount":99.16,"timestamp":1746821110308},"delay":0,"floatShares":780001,"shares":780001,"eps":0,"marketStatus":"Market Closed","change":0.035,"latestTime":"05-09 16:00:00 EDT","open":49.6,"high":49.69,"low":49.57,"amount":197328.6887,"amplitude":0.002422,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":7,"adr":0,"exchange":"AMEX","adjPreClose":49.545,"sharesOutstanding":780001,"nav":49.4269,"aum":38553064.27,"dividendRate":0.024292,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":49.57,"preClose":49.58,"latestTime":"16:05 EDT","volume":2,"amount":99.16,"timestamp":1746821110308},"volumeRatio":1.1248444425977047},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DMX\",,,,,undefined,":{"symbol":"DMX","floatShares":780001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.1248444425977047,"shares":780001,"dividePrice":1.204388,"high":49.69,"amplitude":0.002422,"preClose":49.545,"low":49.57,"week52Low":48.45,"pbRate":"--","week52High":50.4662,"institutionHeld":0,"latestPrice":49.58,"eps":0,"divideRate":0.024292,"volume":3977,"delay":0,"ttmEps":0,"open":49.6,"prevYearClose":50.0239,"prevWeekClose":49.5,"prevMonthClose":49.6282,"prevQuarterClose":49.8,"fiveDayClose":49.5,"twentyDayClose":48.8466,"sixtyDayClose":50.155},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/DMX\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DMX\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532014900","title":"Dimerix Enters License Agreement to Commercialize DMX-200 Drug Candidate in the US, Shares Surge 43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2532014900","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532014900?lang=en_us&edition=fundamental","pubTime":"2025-05-01 09:02","pubTimestamp":1746061329,"startTime":"0","endTime":"0","summary":"Dimerix (ASX:DXB) and Amicus Therapeutics entered into an exclusive license agreement for the commercialization of Dimerix's drug candidate DMX-200 in the US, according to a Thursday Australian bourse","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DMX","FSGS","DXB.AU","BK7067","BK7501","BK7508"],"gpt_icon":0},{"id":"2532601534","title":"Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2532601534","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532601534?lang=en_us&edition=fundamental","pubTime":"2025-05-01 07:12","pubTimestamp":1746054720,"startTime":"0","endTime":"0","summary":"Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis . DMX-200 is in a pivotal Phase 3 trial for FSGS, a rare and fatal kidney disease with no FDA-approved therapies. Dimerix successfully completed Type C meeting with the FDA in March 2025, aligning on proteinuria as the primary endpoint for approval. Dimerix to receive US$30 million  upfront payment, up to US$560 million  for success-based milestone payments, in addition to tiered royalties on DMX-200 net U.S. sales. “We are delighted to partner with Amicus in the United States. The Amicus team has a remarkable history of successfully delivering rare disease medicines to those in need. Their expertise and resources will be crucial to help achieve our mutual objective of commercializing this innovative treatment,” said Dr. Nina Webster, CEO and Managing Director of Dimerix. “I’m grateful to the dedicated Dimerix team, trial participants, and investigators for their contin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dimerix-amicus-therapeutics-announce-exclusive-231200447.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","FOLD","LU2065171311.SGD","DMX","ARB","FSGS","UBCP","LU2065171402.SGD","DXB.AU","DXBO.AU","LU2065169927.USD","LU2065170008.USD","BK4211"],"gpt_icon":0},{"id":"2530460381","title":"FDA Endorsement Boosts Dimerix’s DMX-200 Path to Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2530460381","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530460381?lang=en_us&edition=fundamental","pubTime":"2025-04-28 08:17","pubTimestamp":1745799432,"startTime":"0","endTime":"0","summary":"Dimerix Limited ( ($AU:DXB) ) has issued an announcement. Dimerix Limited announced a significant development in its Phase 3 clinical trial for DMX...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fda-endorsement-boosts-dimerixs-dmx-200-path-to-approval?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fda-endorsement-boosts-dimerixs-dmx-200-path-to-approval?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DMX"],"gpt_icon":0},{"id":"2528216127","title":"DoubleLine Opportunistic Core Bond ETF Marks First Three Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2528216127","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528216127?lang=en_us&edition=fundamental","pubTime":"2025-04-18 01:35","pubTimestamp":1744911300,"startTime":"0","endTime":"0","summary":"DBND Generated Higher Return with Less Risk than Benchmark and Fund Category Average. TAMPA, Fla., April 17, 2025 /PRNewswire/ --The DoubleLine Opportunistic Core Bond ETF , an actively managed exchange-traded fund launched March 31, 2022, on the NYSE Arca electronic exchange, now has a three-year track record.For the three years ended March 31, 2025, the DoubleLine Opportunistic Core Bond ETF  delivered an annualized return of 1.66% . DBND's benchmark, the Bloomberg US Aggregate Bond Index , produced an annualized return of 0.52% for the same period. The average annualized return for DBND's Morningstar fund category, Intermediate Core-Plus Bond, 0.92%. DBND delivered that excess return with less risk than the benchmark and the fund category average as measured by return volatility and maximum drawdown.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/doubleline-opportunistic-core-bond-etf-173500595.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/doubleline-opportunistic-core-bond-etf-173500595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FDN","US3Y.BOND","DCRE","DABS","US12M.BOND","BK4550","US2Y.BOND","US10Y.BOND","DMX","BK4585","US5Y.BOND","CMBS","CAPE","DSL","DMBS","US6M.BOND","NAV","US7Y.BOND","DCMT","DFVE","US30Y.BOND","BK4588"],"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":9,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DMX\",params:#limit:5,,,undefined,":[{"date":"2025-05-01","symbol":"DMX","amount":0.19133,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-01","defaultRemindTime":1746106200000,"name":"DoubleLine Multi-Sector Income ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-07","payableDate":"2025-05-01","currency":"USD","dateTimestamp":1746072000000,"payDate":"2025-05-07"},{"date":"2025-04-01","symbol":"DMX","amount":0.28018,"announcedDate":"2025-03-31","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-01","defaultRemindTime":1743514200000,"name":"DoubleLine Multi-Sector Income ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-07","payableDate":"2025-04-01","currency":"USD","dateTimestamp":1743480000000,"payDate":"2025-04-07"},{"date":"2025-03-03","symbol":"DMX","amount":0.255266,"announcedDate":"2025-02-28","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-03","defaultRemindTime":1741012200000,"name":"DoubleLine Multi-Sector Income ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-07","payableDate":"2025-03-03","currency":"USD","dateTimestamp":1740978000000,"payDate":"2025-03-07"},{"date":"2025-02-03","symbol":"DMX","amount":0.268541,"announcedDate":"2025-01-31","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-03","defaultRemindTime":1738593000000,"name":"DoubleLine Multi-Sector Income ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-07","payableDate":"2025-02-03","currency":"USD","dateTimestamp":1738558800000,"payDate":"2025-02-07"},{"date":"2024-12-23","symbol":"DMX","amount":0.209071,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"DoubleLine Multi-Sector Income ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-30","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DMX\",market:\"US\",,,undefined,":[{"executeDate":"2024-12-23","recordDate":"2024-12-23","paymentDate":"2024-12-30","value":0.209071,"currency":"USD"},{"executeDate":"2025-02-03","recordDate":"2025-02-03","paymentDate":"2025-02-07","value":0.268541,"currency":"USD"},{"executeDate":"2025-03-03","recordDate":"2025-03-03","paymentDate":"2025-03-07","value":0.255266,"currency":"USD"},{"executeDate":"2025-04-01","recordDate":"2025-04-01","paymentDate":"2025-04-07","value":0.28018,"currency":"USD"},{"executeDate":"2025-05-01","recordDate":"2025-05-01","paymentDate":"2025-05-07","value":0.19133,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DMX\",market:\"US\",delay:false,,,undefined,":{}}}